Ken Fujise

Ken Fujise

Auto-generated profile, based on publicly available information

Ken Fujise

Division of Cardiology, Department of Medicine, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
DPDecha Pinkaew
Decha Pinkaew
Abhijnan ChattopadhyayAbhijnan Chattopadhyay
Abhijnan Chattopadhyay
MKMatthew D. King
Matthew D. King
PCPreedakorn Chunhacha
Preedakorn Chunhacha
ZLZhihe Liu
Zhihe Liu
KFKen Fujise
Ken Fujise
The endoplasmic reticulum, the cytoplasmic organelle that matures a massive amount of nascent secretory polypeptides, is particularly sensitive to stress. Endoplasmic reticulum stress causes unfolded proteins to populate the organelle, eliciting the unfolded protein response. During the unfolded protein response, GRP78—an endoplasmic reticulum master stress regulator—detaches from three endoplasmic reticulum stress sensors (IRE1α, PERK, and ATF6) and allows them to activate the apoptotic signaling pathway. Fortilin, a pro-survival molecule, is known to inhibit apoptosis by binding and inhibiting p53, but its role in endoplasmic reticulum stress-induced apoptosis remains unknown. Here, we report that fortilin directly interacts with the cytoplasmic domain of IRE1α, inhibits both kinase and endoribonuclease (RNase) activities of the stress sensor, and protects cells against apoptotic cell death at both cellular and whole animal levels. Our data support a role of fortilin in the unfolded protein response and its potential participation in human diseases caused by unfolded protein response.

23 September 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
DCDunpeng Cai
Dunpeng Cai
CSChenming Sun
Chenming Sun
GZGui Zhang
Gui Zhang
XQXingyi Que
Xingyi Que
KFKen Fujise
Ken Fujise
SCShiyou Chen
Shiyou Chen
Rationale: Abdominal aortic aneurysm (AAA) is a permanent and localized dilatation of abdominal aorta with potentially fatal consequence of aortic rupture. No effective pharmacological approach has been identified to limit AAA progression and rupture. AAA is characterized by extensive aortic wall matrix degradation that contributes to arterial wall remodeling and eventual rupture, in which smooth muscle cell (SMC) phenotypic transition and MMPs (matrix metalloproteinases), especially MMP2 (matrix metalloproteinase-2) and MMP9, play critical roles. Objective: Our previous study showed that ADAR1 (adenosine deaminases acting on RNA 1) regulates SMC phenotype, which prompted us to study if ADAR1 is involved in AAA development. Methods and Results: We used Ang II (angiotensin II) infusion ApoE −/− mouse model combined with ADAR1 global and SMC-specific knockout to study the role of ADAR1 in AAA formation/dissection. Aortic transplantation was conducted to determine the importance of vascular cell ADAR1 in AAA development/dissection. Primary cultured SMC were used to study how ADAR1 regulates the inflammatory SMC phenotype and MMP production/activity. Patient specimens were obtained to investigate the relevance of ADAR1 expression to human AAA disease. ADAR1 was induced in abdominal aortic SMC in both mouse and human AAA tissues. Heterozygous knockout of ADAR1 diminished the Ang II–induced AAA/dissection in ApoE −/− mice. Mouse aortic transplantation showed that ADAR1 in vascular cells was essential for AAA formation. SMC-specific ADAR1 knockout reduced experimental AAA formation/dissection. Mechanistically, ADAR1 interacted with HuR (human antigen R) to increase the stability of MMP2 and MMP9 mRNA, leading to increased MMP levels and activities. Conclusions: ADAR1 is novel regulator of AAA development/dissection, and thus may represent a potential new therapeutic target to hinder AAA growth and rupture.

1 September 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YCYanjie Chen
Yanjie Chen
TFTakayuki Fujita
Takayuki Fujita
DZDi Zhang
Di Zhang
HDHung Doan
Hung Doan
DPDecha Pinkaew
Decha Pinkaew
KFKen Fujise
Ken Fujise
Tumor suppressor protein p53, our most critical defense against tumorigenesis, can be made powerless by mechanisms such as mutations and inhibitors. Fortilin, a 172-amino acid polypeptide with potent anti-apoptotic activity, is up-regulated in many human malignancies. However, the exact mechanism by which fortilin exerts its anti-apoptotic activity remains unknown. Here we present significant insight. Fortilin binds specifically to the sequence-specific DNA binding domain of p53. The interaction of fortilin with p53 blocks p53-induced transcriptional activation of Bax. In addition, fortilin, but not a double point mutant of fortilin lacking p53 binding, inhibits p53-dependent apoptosis. Furthermore, cells with wild-type p53 and fortilin, but not cells with wild-type p53 and the double point mutant of fortilin lacking p53 binding, fail to induce Bax gene and apoptosis, leading to the formation of large tumor in athymic mice. Our results suggest that fortilin is a novel p53-interacting molecule and p53 inhibitor and that it is a logical molecular target in cancer therapy.

4 March 2008 in FEBS Letters
Verified
Journal Article
Closed access
TFTakayuki Fujita
Takayuki Fujita
KFKumar Felix
Kumar Felix
DPDecha Pinkaew
Decha Pinkaew
NHNongporn Hutadilok-Towatana
Nongporn Hutadilok-Towatana
ZLZhihe Liu
Zhihe Liu
KFKen Fujise
Ken Fujise

Verified
Journal Article
Open access
PDF file
SKSrikruthi Sai Krishnachaitanya
Srikruthi Sai Krishnachaitanya
MLMax Liu
Max Liu
KFKen Fujise
Ken Fujise
QLQingjie Li
Qingjie Li
Inflammatory bowel disease (IBD), classified primarily between Crohn’s disease and ulcerative colitis, is a collection of chronic gastrointestinal inflammatory conditions that cause multiple complications because of systemic alterations in the immune response. One major player is microRNA (miRNA), which is found to be associated with multiple pathways in mediating inflammation, especially those of a chronic nature in IBD, as well as irritable bowel syndrome. Although there have been studies linking miRNA alterations in IBD, even differentiating Crohn’s disease and ulcerative colitis, this review focuses mainly on how miRNAs cause and mechanistically influence the pathologic complications of IBD. In addition to its role in the well-known progression towards colorectal cancer, we also emphasize how miRNA manifests the many extraintestinal complications in IBD such as cardiovascular diseases; neuropsychiatric conditions such as depression and anxiety disorders; and others, including various musculoskeletal, dermatologic, ocular, and hepatobiliary complications. We conclude through a description of its potential use in bettering diagnostics and the future treatment of IBD and its systemic symptoms.

4 January 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Abhijnan ChattopadhyayAbhijnan Chattopadhyay
Abhijnan Chattopadhyay
DPDecha Pinkaew
Decha Pinkaew
HDHung Q. Doan
Hung Q. Doan
RJReed B. Jacob
Reed B. Jacob
SVSunil K. Verma
Sunil K. Verma
KFKen Fujise
Ken Fujise
Fortilin, a pro-survival molecule, inhibits p53-induced apoptosis by binding to the sequence-specific DNA-binding domain of the tumor suppressor protein and preventing it from transcriptionally activating Bax. Intriguingly, fortilin protects cells against ROS-induced cell death, independent of p53. The signaling pathway through which fortilin protects cells against ROS-induced cell death, however, is unknown. Here we report that fortilin physically interacts with the antioxidant enzyme peroxiredoxin-1 (PRX1), protects it from proteasome-mediated degradation and keeps it enzymatically active by blocking its deactivating phosphorylation by Mst1, a serine/threonine kinase. At the whole animal level, the liver-specific overexpression of fortilin reduced PRX1 phosphorylation in the liver, enhanced PRX1 activity and protected the transgenic animals against alcohol-induced, ROS-mediated, liver damage. These data suggest the presence of a novel oxidative-stress-handling pathway where the anti-p53 molecule fortilin augments the peroxidase PRX1 by protecting it against degradation and inactivation of the enzyme. Fortilin-PRX1 interaction in the liver could be clinically exploited further to prevent acute alcohol-induced liver damage in humans.